AIM ImmunoTech Provides Routine Update on Annual Filings
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) disclosed that its audited consolidated financial statements for the year ended December 31, 2025 include an independent auditor's going concern emphasis of matter. This disclosure is required by NYSE American Section 610(b) and does not amend prior filings.
The company said management remains confident in its ability to raise funds and highlighted positive progress in the Phase 2 DURIPANC study of Ampligen plus durvalumab for metastatic pancreatic cancer; the next DURIPANC update is expected in June 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- DURIPANC Phase 2 showed reported positive progress
- Next DURIPANC update scheduled for June 2026
Negative
- Auditor going concern emphasis noted in 2025 audited financials
News Market Reaction – AIM
On the day this news was published, AIM gained 8.96%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.6% during that session. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $396K to the company's valuation, bringing the market cap to $4.82M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Investor event announcement | Neutral | -6.2% | Virtual investor Closing Bell event and corporate overview scheduled. |
| Mar 18 | Patent approval | Positive | +43.7% | Final approval of Japanese patent for Ampligen with cancer indications. |
| Mar 06 | Rights offering closing | Negative | +4.3% | Closing of rights offering raising about $1.8M via preferred and warrants. |
| Mar 04 | Rights offering results | Negative | -1.3% | Preliminary results of rights offering with aggregate $1.8M subscriptions. |
| Mar 02 | Phase 3 planning | Positive | -14.9% | Agreement to design proposed Phase 3 Ampligen trial in pancreatic cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: strong gains on IP wins, pressure on positive clinical planning, and uneven responses to offerings.
Over the last few months, AIM has balanced financing needs with oncology development. A rights offering in early March 2026 targeted roughly $1.8 million, with mixed price reactions around the announcement and closing. In contrast, a Japanese patent win for Ampligen with protection into 2039 saw a 43.66% gain. A March Phase 3 planning agreement for Ampligen in late-stage pancreatic cancer coincided with a -14.89% move. Today’s going-concern emphasis follows prior filings that highlighted equity deficits and capital-raising plans.
Key Terms
going concern financial
phase 2 medical
immune checkpoint inhibitor medical
metastatic medical
folfirinox medical
stable disease medical
pd-l1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.
AIM management is confident in its continued ability to raise funds based on ongoing, promising results in the development of its lead drug, Ampligen, for the treatment of late-stage pancreatic cancer. The Company recently reported positive progress in the Phase 2 clinical study evaluating Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study). AIM expects to release the next DURIPANC update in June 2026.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. No assurance can be given that intention to seek Orphan Drug Designation will result in the granting of that status, nor that the possession of Orphan Drug Designations or any patents means that a drug will receive market approval. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the Registration Statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com